Dublin, April 28, 2025 (GLOBE NEWSWIRE) -- The "Therapeutics for Women's Health: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.
The global therapeutics for women's health technologies market is expected to grow from $61.5 billion in 2024 and is projected to reach $81.2 billion by the end of 2029, at a compound annual growth rate (CAGR) of 5.7% during the forecast period of 2024 to 2029.
In 2023, the global therapeutics for women's health technologies market was valued at $58.3 billion. The market is forecast to grow at a CAGR of 5.7% to reach $81.2 billion by the end of 2029.
The factors driving market growth are the growing population of older women and the rising awareness of and accessibility to healthcare and advanced therapeutic products. High treatment costs and regulatory challenges are restraining the market's growth. In 2023, the breast cancer segment of the global therapeutics for women's health technologies held the largest share, 55.1% of the market segmented by women's health disorders, and this segment is expected to grow at a CAGR of 5.9% during the forecast period.
Report Scope
This report provides a detailed analysis of the global therapeutics for women's health technologies market, including coverage of market drivers, restraints and opportunities. It also includes analyses of this market's competitive environment and products.
The report presents market estimates and forecasts for women's health therapeutics and provides market projections through 2029. For this analysis, the market is segmented by conditions related to women's health, including breast cancer, postmenopausal osteoporosis, menopause, endometriosis and polycystic ovary syndrome (PCOS), and by geographic region. The report provides company profiles of the market's leading players that feature detailed information about each company's business segments, financials, product portfolios and recent developments.
By region, the global therapeutics for women's health technologies market is segmented into North America, Europe, Asia-Pacific and the Rest of the World (RoW). The North American region includes the U.S., Canada and Mexico. Europe includes the U.K., Germany, Spain, France, Italy and the Rest of Europe; Asia-Pacific comprises China, Japan, India, Australia, South Korea and the Rest of Asia-Pacific. The rest of the World includes the Middle East and Africa, and South America.
In the report's market estimates, 2021 and 2022 serve as historical years, 2023 as the base year, and data forecasts are given through 2029.
The report includes:
- 46 data tables and 63 additional tables
- An overview of the global market and technologies for women's health therapeutics
- Analyses of the global market trends, with sales data for 2021-2023, estimates for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Study of women's diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS), including their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment options
- Discussion on aging and women's health disorders, women and sexual health such as female sexual arousal disorder, female orgasmic disorder and vaginismus, as well as the relationship between infertility and cancer
- Information about significant products, companies, issues and trends affecting the women's disorders and diseases industry
- Evaluation of the impact of demographic, economic and other factors that will drive demand in the market for women's health therapeutics
- Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
- Identification of the market drivers, restraints and other forces impacting the global market, as well as an evaluation of current and projected market size
- A discussion of ESG challenges and practices in the industry
- Market share analysis of the key companies and coverage of their proprietary technologies, strategic alliances, and other market strategies
- Profiles of the leading companies, including F. Hoffmann-La Roche Ltd., Pfizer Inc., Eli Lilly and Company, Novartis AG and Amgen Inc.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 159 |
| Forecast Period | 2024 - 2029 |
| Estimated Market Value (USD) in 2024 | $61.5 Billion |
| Forecasted Market Value (USD) by 2029 | $81.2 Billion |
| Compound Annual Growth Rate | 5.7% |
| Regions Covered | Global |
Key Topics Covered:
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Insights
Chapter 2 Market Overview
- Overview
- Definitions
- Breast Cancer
- Postmenopausal Osteoporosis
- Menopause
- Endometriosis
- Polycystic Ovary Syndrome (PCOS)
- Historical Context
- Aging and Women's Health Disorders
Chapter 3 Market Dynamics
- Market Drivers
- Rising Population of Older Women
- Increasing Awareness and Accessibility
- Market Restraints
- High Treatment Costs
- Regulatory Challenges
- Market Opportunities
- Advances in Personalized Medicine
- Emerging Markets
Chapter 4 Emerging Technologies
- Digital Health Solutions
- Advanced Fertility Technologies
- Targeted Biologics and Biosimilars
- Nanotechnology-Driven Drug Delivery
- Gene Therapy and CRISPR
Chapter 5 Pipeline Assessment and Analysis
- Women's Health Therapeutics: Key Clinical Trial Developments
- Drugs in Pipeline
- Overview of Osteoporosis Drug Development Pipeline
Chapter 6 Regulatory Structure
- Overview of Regulations
- U.S.
- Drug Development and Approval Process
- Types of Applications Reviewed by FDA
- Canada
- Food and Drugs Act (F-27)
- Europe
- Japan
Chapter 7 Market Segmentation Analysis
- Market Analysis, by Women's Health Disorder
- Breast Cancer
- Postmenopausal Osteoporosis
- Menopause
- Endometriosis
- PCOS
- Market Analysis, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 8 Competitive Landscape
- Market Players and Strategies
- Patent Analysis
- Key Developments
Chapter 9 ESG Perspective
- ESG Goals for the Pharmaceutical Sector
- Focus on Energy Efficiency
- Reduce Emissions and Carbon Footprint
- Waste Generation and Disposal
- Manufacturing, Distribution and Transportation
- Social Responsibility
- Governance
- ESG Risk Ratings in the Pharmaceutical Industry
Company Profiles
- AbbVie Inc.
- Amgen Inc.
- Asahi Kasei Corp.
- AstraZeneca
- Bayer AG
- Bristol-Myers Squibb Co.
- Eisai Co. Ltd.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services Inc.
- Lilly
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/c1kb4c
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
